Please login to the form below

What pharma needs to know about genomic data in 2016

Consultant David Cooney from Blue Latitude Health talks us through what this progress in genomics means for pharma in 2016.
Since the Genome Project started in 1990, genetics has been the “great hope” of healthcare, promising to solve the great mystery of how illness and disease affect us on an individual level. About ten years ago, personalised medicine was a major step forward – tailoring treatments based on individual patient history and information. Fast forward to 2016, and investigating the central dogma of biology is still a major focus of healthcare research.

Now, more researchers are adopting a systems biology approach, combining genetic data with phenotypic data, such as patient records and clinical information, along with metabolomoics and epigenomics. At the forefront of this trend are Human Longevity Inc. and Calico, who are leveraging this multi-discipline approach to target the single biggest risk factor in all human disease – ageing.

Consultant David Cooney talks us through what this progress in genomics means for pharma in 2016.


Partnerships between major players will be increasingly important

Partnerships between companies like the Human Longevity Inc. (HLI), Calico, 23andme, and the award-winning Color Genomics mean that we’ll start to see some innovative research and development work in this area. While this may seem like future-gazing, the reality is that pharma companies are already collaborating with these companies.

Work by HLI in partnership with Calico is incredibly important because it’s pushing this research into the clinic to impact patient care. We believe 2016 will be the year we start to see the fruits of these partnerships emerge from R&D into the commercial space with innovative, genetic-based services. Which means that pharma needs to consider whether their value proposition will still hold if the competition is able to support their brands with genomic data.


Download the full article from Blue Latitude Health here


3rd February 2016

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Digital Nation: How Australia became a digital health pioneer
Australia has adopted digital strategies to transform its healthcare system. We sat down with Rachel de Sain, who shares where, and how she contributed to improving digital health products and services in Australia to advance their nation to becoming one of the world's leaders in digital health.
Blue Latitude Health
Rethinking Electronic Medical Records
EMR systems are far from perfect. Clinician and PhD candidate Dr. Pao takes us through his perspective on the system and how he aims to lead the way by solving the challenges when adopting this technology in a clinical setting.
Blue Latitude Health
Blue Latitude Health moves to new offices in New York
Blue Latitude Health has moved offices to a new location in New York following a year of substantial growth.
Blue Latitude Health
Designing a global digital patient services platform
Within our customer experience capability at Blue Latitude Health, our UX researchers and designers are tasked with understanding customer and client needs. Recently, a client required a centralised system to drive the development and deployment of data-driven patient services. Here, we explain the process of developing this platform.
Blue Latitude Health
Digital therapeutics and their impact on society
Head of Customer Experience Elisa del Galdo explores how healthcare technology can help chronic disease patients and asks what makes a good digital therapeutic?
Blue Latitude Health
Life with multiple myeloma - why I'm a lucky man living the dream
Multiple myeloma patient Bob Munro explains what it's like to live with the rare blood cancer and how his diagnosis led him on the journey of a lifetime – cycling from London to the Arc de Triomphe.
Blue Latitude Health